| First Author | Mao JH | Year | 2004 |
| Journal | Genes Dev | Volume | 18 |
| Issue | 15 | Pages | 1800-5 |
| PubMed ID | 15289454 | Mgi Jnum | J:91661 |
| Mgi Id | MGI:3050162 | Doi | 10.1101/gad.1213804 |
| Citation | Mao JH, et al. (2004) Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev 18(15):1800-5 |
| abstractText | Pten heterozygous (Pten+/-) mice develop increased papilloma numbers and show decreased carcinoma latency time in comparison with controls after skin treatment with dimethyl benzanthracene (DMBA) and tetradecanoyl-phorbol acetate (TPA). H-ras mutation is normally a hallmark of DMBA-TPA-induced skin tumors, but 70% of carcinomas from Pten+/- mice do not exhibit this mutation, and in all cases have lost the wild-type Pten allele. Tumors that retain the Pten wild-type allele also have H-ras mutations, indicating that activation of H-ras and complete loss of Pten are mutually exclusive events in skin carcinomas. Mitogen-activated protein kinase (MAPK) is consistently activated in the tumors with H-ras mutations, but is strongly down-regulated in Pten-/- tumors, suggesting that this pathway is dispensable for skin carcinoma formation. These data have important implications in designing individual therapeutic strategies for the treatment of cancer. |
